Gerd

Pune, India, July 11, 2023 (GLOBE NEWSWIRE) -- The Insight Partners latest study on "Gastrointestinal Drugs Market Size Report, Forecast to 2027 – COVID-19 Impact and Global Analysis – by…

Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023Combined launch of vonoprazan for Erosive GERD and H. pylori indications planned for Q4 2023, if approved FLORHAM PARK,…

This study has studied the genetic material of 7,66,000 individuals. It particularly studied the cognitive abilities of individuals with , and gastro-duodenitis. …

Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn free days as compared to placebo…

FLORHAM PARK, N.J., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments…

Results from an investigational Phase 3 PHALCON-EE trial demonstrating superior healing at week 2 in patients with LA Grade C/D (moderate-to-severe) erosive esophagitis and superior…

…

Fifteen years after a laparoscopic partial or total fundoplication for chronic gastroesophageal…

FLORHAM PARK, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and…

Vonoprazan met the primary endpoint for all three dose levels (10 mg, 20 mg, 40 mg) taken on-demand, demonstrating faster and sustained relief of episodic heartburn as compared to placebo…